D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSE:OSTX)

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock.

Separately, Maxim Group raised their target price on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, January 16th.

OS Therapies Price Performance

NYSE:OSTX opened at $1.62 on Monday. The business’s 50-day moving average is $1.92 and its two-hundred day moving average is $2.74. OS Therapies has a 12 month low of $1.41 and a 12 month high of $7.00.

Insider Activity at OS Therapies

In related news, major shareholder Shalom Auerbach sold 100,000 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $2.84, for a total value of $284,000.00. Following the completion of the transaction, the insider now owns 2,431,211 shares of the company’s stock, valued at approximately $6,904,639.24. This represents a 3.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC increased its stake in OS Therapies Inc (NYSE:OSTX) by 120.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the period. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 at the end of the most recent reporting period.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.